Related Experiment Video
Updated: Sep 20, 2025
09:21
Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
Published on: July 7, 2023
1.7K
New Perspectives on Parkinson's Disease Subtyping: A Narrative Review
Charlie Buchmann1, Manon Bouchard2,3
1Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
Summary
Biomarkers offer new ways to subtype Parkinson's disease (PD), understand its causes, and predict patient outcomes. This helps personalize treatments and advance the development of disease-modifying therapies for PD.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Parkinson's disease (PD) is a complex neurodegenerative disorder with varied pathophysiology and clinical symptoms.
- Objective biomarkers are crucial for understanding PD heterogeneity and identifying therapeutic targets.
Purpose of the Study:
- To review the role of genetic, imaging, and biochemical biomarkers in subtyping PD.
- To explore how biomarkers can predict clinical phenotypes, disease progression, and treatment response.
Main Methods:
- Review of studies on genetic biomarkers (SNCA, LRRK2, GBA, PRKN) and associated phenotypes.
- Exploration of imaging biomarkers, specifically MRI brain atrophy patterns, for PD subtyping.
- Review of blood, cerebrospinal fluid (CSF), and urine biomarkers for monitoring PD progression.
Main Results:
- Specific genes like GBA are linked to distinct PD phenotypes, often including nonmotor features.
- Imaging biomarkers, such as MRI-defined atrophy patterns, can define robust PD subtypes.
- Various biomarkers aid in monitoring disease progression across motor, cognitive, autonomic, and psychiatric domains.
Conclusions:
- Biomarkers provide objective methods for PD subtyping and understanding pathophysiology.
- Individualized symptomatic treatments and improved clinical trial designs are facilitated by biomarker research.
- Biomarker advancements bring us closer to discovering effective disease-modifying therapies for Parkinson's disease.
More Related Videos
Related Concept Videos
01:15Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
01:24Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
01:37Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K